PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28064234-1	2017	AIM: To evaluate the short-term effects of calcitriol and sevelamer hydrochloride on fibroblast growth factor-23 (FGF23) in humans and to determine whether the effect is direct or indirect through calcitriol-induced increased absorption of phosphorus from the intestine.	sevelamer	58-81	fibroblast growth factor 23	Homo sapiens	85-112
27434393-0	2016	Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.	sevelamer	56-75	vitamin D receptor	Homo sapiens	79-97
26666254-5	2016	In chicks where dietary phosphate was primarily in the form of phytate, 4 selected hIAP antibodies inhibited 1alpha-(OH) D3-induced increases in blood phosphate, one of which, generated against selected peptide (MFPMGTPD), was as effective as sevelamer hydrochloride in preventing the 1alpha-(OH) D3-induced increase in blood phosphate, but ineffective in preventing an increase in body weight gain and bone ash induced by 1alpha-(OH) D3.	sevelamer	243-266	alkaline phosphatase, intestinal	Homo sapiens	83-87
27342212-13	2016	Administration of oral antibiotics or sequestration of bacterial endotoxins with sevelamer hydrochloride reduced mucosal inflammation and restored normal liver histology in F11r(-/-) mice fed a HFCD.	sevelamer	81-104	F11 receptor	Mus musculus	173-177
27070162-9	2016	A decrease in FGF-23 and PHT levels was achieved chiefly in the patients who had used phosphate-binders that contained no calcium (sevelamer hydrochloride).	sevelamer	131-154	fibroblast growth factor 23	Homo sapiens	14-20
23975746-9	2013	However, sevelamer-HCl, but not with calcium acetate, led to a significant decrease in serum FGF-23, sclerostin and leptin, and to a significant increase in bone alkaline phosphatase levels.	sevelamer	9-22	fibroblast growth factor 23	Homo sapiens	93-99
24131677-9	2013	Subjects with a history of smoking or coronary revascularization had significantly higher CRP levels, while subjects treated with sevelamer hydrochloride had significantly lower CRP.	sevelamer	130-153	C-reactive protein	Homo sapiens	178-181
24131677-12	2013	Treatment with sevelamer hydrochloride is associated with lower CRP in HD patients.	sevelamer	15-38	C-reactive protein	Homo sapiens	64-67
23975746-9	2013	However, sevelamer-HCl, but not with calcium acetate, led to a significant decrease in serum FGF-23, sclerostin and leptin, and to a significant increase in bone alkaline phosphatase levels.	sevelamer	9-22	sclerostin	Homo sapiens	101-111
23975746-9	2013	However, sevelamer-HCl, but not with calcium acetate, led to a significant decrease in serum FGF-23, sclerostin and leptin, and to a significant increase in bone alkaline phosphatase levels.	sevelamer	9-22	leptin	Homo sapiens	116-122
23574727-7	2013	Amongst the EF and pro-inflammatory biomarkers, sevelamer carbonate decreased serum endothelin-1, plasminogen activator inhibitor-1, C-reactive protein and interleukin-6.	sevelamer	48-67	endothelin 1	Homo sapiens	84-131
23787550-0	2013	A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.	sevelamer	56-65	fibroblast growth factor 23	Homo sapiens	91-118
23574727-7	2013	Amongst the EF and pro-inflammatory biomarkers, sevelamer carbonate decreased serum endothelin-1, plasminogen activator inhibitor-1, C-reactive protein and interleukin-6.	sevelamer	48-67	C-reactive protein	Homo sapiens	133-151
23574727-7	2013	Amongst the EF and pro-inflammatory biomarkers, sevelamer carbonate decreased serum endothelin-1, plasminogen activator inhibitor-1, C-reactive protein and interleukin-6.	sevelamer	48-67	interleukin 6	Homo sapiens	156-169
23357670-2	2013	Sevelamer hydrochloride (Renagel ); a non-calcium phosphate binder reduces coronary artery and aortic calcification as compared to calcium containing phosphate binders and additionally effects inflammatory biomarkers such as C-reactive protein (CRP), and lowers LDL cholesterol in patients with CKD.	sevelamer	0-23	C-reactive protein	Homo sapiens	225-243
23357670-2	2013	Sevelamer hydrochloride (Renagel ); a non-calcium phosphate binder reduces coronary artery and aortic calcification as compared to calcium containing phosphate binders and additionally effects inflammatory biomarkers such as C-reactive protein (CRP), and lowers LDL cholesterol in patients with CKD.	sevelamer	0-23	C-reactive protein	Homo sapiens	245-248
23357670-2	2013	Sevelamer hydrochloride (Renagel ); a non-calcium phosphate binder reduces coronary artery and aortic calcification as compared to calcium containing phosphate binders and additionally effects inflammatory biomarkers such as C-reactive protein (CRP), and lowers LDL cholesterol in patients with CKD.	sevelamer	25-32	C-reactive protein	Homo sapiens	225-243
23357670-2	2013	Sevelamer hydrochloride (Renagel ); a non-calcium phosphate binder reduces coronary artery and aortic calcification as compared to calcium containing phosphate binders and additionally effects inflammatory biomarkers such as C-reactive protein (CRP), and lowers LDL cholesterol in patients with CKD.	sevelamer	25-32	C-reactive protein	Homo sapiens	245-248
22742720-0	2012	Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.	sevelamer	94-113	fibroblast growth factor 23	Homo sapiens	0-27
22859851-5	2012	Treating Npt2b-deficient mice with the phosphate binder sevelamer carbonate further reduced serum phosphate levels.	sevelamer	56-75	solute carrier family 34 (sodium phosphate), member 2	Mus musculus	9-14
23774446-3	2013	METHODS: We performed a prospective cohort study examining the effect of phosphorus reduction with sevelamer carbonate on FGF23 levels in CKD patients.	sevelamer	99-118	fibroblast growth factor 23	Homo sapiens	122-127
19145073-0	2009	Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification.	sevelamer	109-128	renin	Rattus norvegicus	16-21
22461535-7	2012	Total cholesterol and fibroblast growth factor 23 were reduced by sevelamer carbonate, relative to calcium carbonate.	sevelamer	66-85	fibroblast growth factor 23	Homo sapiens	22-49
22461535-8	2012	AGE receptor 1 and sirtuin 1 mRNA were increased and PMNC TNFalpha levels were decreased by sevelamer carbonate, but not calcium carbonate.	sevelamer	92-111	tumor necrosis factor	Homo sapiens	58-66
22461535-11	2012	CONCLUSIONS: Sevelamer carbonate significantly reduces HbA1c, fibroblast growth factor 23, lipids, and markers of inflammation and oxidative stress, and markedly increases antioxidant markers, independently of phosphorus in patients with diabetes and early kidney disease.	sevelamer	13-32	fibroblast growth factor 23	Homo sapiens	62-89
22260362-1	2012	OBJECTIVE: To investigate the effects of phosphonoformic acid (PFA) and sevelamer hydrochloride (Renagel) on renal type IIa sodium-dependent phosphate cotransporter (NaPi-2) mRNA expression in hyperphosphatemia rats.	sevelamer	72-95	solute carrier family 34 member 1	Rattus norvegicus	166-172
22260362-1	2012	OBJECTIVE: To investigate the effects of phosphonoformic acid (PFA) and sevelamer hydrochloride (Renagel) on renal type IIa sodium-dependent phosphate cotransporter (NaPi-2) mRNA expression in hyperphosphatemia rats.	sevelamer	97-104	solute carrier family 34 member 1	Rattus norvegicus	166-172
16279016-0	2005	[Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride].	sevelamer	76-99	parathyroid hormone	Homo sapiens	46-49
18423809-2	2008	Because sevelamer decreases low-density lipoprotein cholesterol (LDL-C) levels, we hypothesized that intensive lowering of LDL-C levels with atorvastatin in hemodialysis patients treated with calcium acetate would result in CAC progression rates similar to those in sevelamer-treated patients.	sevelamer	8-17	component of oligomeric golgi complex 2	Homo sapiens	65-70
18423809-2	2008	Because sevelamer decreases low-density lipoprotein cholesterol (LDL-C) levels, we hypothesized that intensive lowering of LDL-C levels with atorvastatin in hemodialysis patients treated with calcium acetate would result in CAC progression rates similar to those in sevelamer-treated patients.	sevelamer	8-17	component of oligomeric golgi complex 2	Homo sapiens	123-128
18506105-5	2008	In addition, THP-1-derived monocytes were co-incubated with supernatants of sevelamer hydrochloride and ET.	sevelamer	76-99	GLI family zinc finger 2	Homo sapiens	13-18
18506105-9	2008	The 1-hour dose-dependent ET-binding effect of sevelamer hydrochloride translated into a marked reduction in TNF-alpha levels.	sevelamer	47-70	tumor necrosis factor	Homo sapiens	109-118
18028171-0	2007	Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.	sevelamer	0-23	parathyroid hormone	Homo sapiens	119-138
16395276-3	2006	We proposed that changes in serum PTH and FGF23 levels might be associated with changes in serum phosphorus levels caused by the phosphate binder sevelamer hydrochloride (sevelamer, i.e. crosslinked poly[allylamine hydrochloride]).	sevelamer	146-169	parathyroid hormone	Rattus norvegicus	34-37
16395276-3	2006	We proposed that changes in serum PTH and FGF23 levels might be associated with changes in serum phosphorus levels caused by the phosphate binder sevelamer hydrochloride (sevelamer, i.e. crosslinked poly[allylamine hydrochloride]).	sevelamer	146-169	fibroblast growth factor 23	Rattus norvegicus	42-47
16395276-3	2006	We proposed that changes in serum PTH and FGF23 levels might be associated with changes in serum phosphorus levels caused by the phosphate binder sevelamer hydrochloride (sevelamer, i.e. crosslinked poly[allylamine hydrochloride]).	sevelamer	146-155	parathyroid hormone	Rattus norvegicus	34-37
16395276-3	2006	We proposed that changes in serum PTH and FGF23 levels might be associated with changes in serum phosphorus levels caused by the phosphate binder sevelamer hydrochloride (sevelamer, i.e. crosslinked poly[allylamine hydrochloride]).	sevelamer	146-155	fibroblast growth factor 23	Rattus norvegicus	42-47
16279016-3	2005	However, by one side, much rises of i-PTH are observed by most patients with change to sevelamer hydrochloride.	sevelamer	87-110	parathyroid hormone	Homo sapiens	38-41
16076378-0	2005	Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.	sevelamer	0-23	fibroblast growth factor 23	Homo sapiens	61-88
16076378-6	2005	Serum FGF23 levels significantly decreased after 4 weeks of the treatment with sevelamer hydrochloride+CaCO3 from the pretreatment levels (P<0.05), while no changes were found in the patients treated with CaCO3 alone.	sevelamer	79-102	fibroblast growth factor 23	Homo sapiens	6-11
16076378-7	2005	Thus, the use of sevelamer hydrochloride and CaCO3 reduced serum FGF23 levels in dialysis patients presumably through inhibiting phosphate load into the intestine.	sevelamer	17-40	fibroblast growth factor 23	Homo sapiens	65-70
15012693-5	2003	To prevent hypercalcemia, non-calcium containing phosphorus binder (sevelamer hydrochloride) and vitamin D analogues, which suppress PTH secretion with minimum calcemic action, have been developed.	sevelamer	68-91	parathyroid hormone	Homo sapiens	133-136
14733418-0	2003	Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.	sevelamer	13-36	parathyroid hormone	Homo sapiens	110-129
10939763-0	2000	Greater PTH suppression in dialysis patients taking sevelamer hydrochloride (Renagel).	sevelamer	52-75	parathyroid hormone	Homo sapiens	8-11
10939763-0	2000	Greater PTH suppression in dialysis patients taking sevelamer hydrochloride (Renagel).	sevelamer	77-84	parathyroid hormone	Homo sapiens	8-11
34901050-14	2021	Pro-inflammatory cytokines were predominantly downregulated by TNF-alpha in the group that ingested sevelamer hydrochloride in the final determination at 6 months of follow-up.	sevelamer	100-123	tumor necrosis factor	Homo sapiens	63-72
29846719-12	2019	CONCLUSIONS: Overall, 1 year of sucroferric oxyhydroxide or sevelamer treatment significantly reduced serum FGF-23, which has been associated with clinical benefit in patients with CKD.	sevelamer	60-69	fibroblast growth factor 23	Homo sapiens	108-114
30013785-8	2018	This is in contrast to the study by Lewis and colleagues, which found significant increases in ferritin and transferrin saturation levels in patients receiving ferric citrate versus active control (calcium acetate and/or sevelamer carbonate) after 52 weeks of therapy.	sevelamer	221-240	transferrin	Homo sapiens	108-119
29074818-0	2017	Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.	sevelamer	29-48	klotho	Homo sapiens	58-64
29074818-0	2017	Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.	sevelamer	29-48	fibroblast growth factor 23	Homo sapiens	69-96
29074818-2	2017	The aim of the FGF23 Reduction Efficacy of a New Phosphate Binder in CKD Trial was to evaluate the effect of sevelamer carbonate on serum C-terminal fibroblast growth factor 23 levels in normophosphatemic patients with CKD stage 3b/4.	sevelamer	109-128	fibroblast growth factor 23	Homo sapiens	149-176
29074818-13	2017	CONCLUSIONS: In our double-blind, placebo-controlled, randomized study performed in normophosphatemic patients with CKD, a 12-week course of sevelamer carbonate significantly reduced phosphaturia without changing serum phosphorus but did not significantly modify serum C-terminal fibroblast growth factor 23 and intact fibroblast growth factor 23 or alpha-klotho levels.	sevelamer	141-160	fibroblast growth factor 23	Homo sapiens	280-307
29074818-13	2017	CONCLUSIONS: In our double-blind, placebo-controlled, randomized study performed in normophosphatemic patients with CKD, a 12-week course of sevelamer carbonate significantly reduced phosphaturia without changing serum phosphorus but did not significantly modify serum C-terminal fibroblast growth factor 23 and intact fibroblast growth factor 23 or alpha-klotho levels.	sevelamer	141-160	fibroblast growth factor 23	Homo sapiens	319-346
29074818-13	2017	CONCLUSIONS: In our double-blind, placebo-controlled, randomized study performed in normophosphatemic patients with CKD, a 12-week course of sevelamer carbonate significantly reduced phosphaturia without changing serum phosphorus but did not significantly modify serum C-terminal fibroblast growth factor 23 and intact fibroblast growth factor 23 or alpha-klotho levels.	sevelamer	141-160	klotho	Homo sapiens	356-362
16272626-5	2005	However, by switching from precipitated calcium carbonate to sevelamer hydrochloride, the calcium level dropped, and as a result the intact PTH rose.	sevelamer	61-84	parathyroid hormone	Homo sapiens	140-143
12771309-2	2003	Dietary phosphate restriction and sevelamer hydrochloride, a calcium-free phosphate binder, suppress parathyroid hormone (PTH) secretion and PTG hyperplasia in experimental animals with CRI, independently of serum calcium and 1,25(OH)(2)D(3) concentrations.	sevelamer	34-57	parathyroid hormone	Rattus norvegicus	101-120
32415923-1	2020	This study aimed to observe and analyze the effect of calcitriol combined with sevelamer carbonate on serum parathyroid hormone in patients with chronic renal failure.	sevelamer	79-98	parathyroid hormone	Homo sapiens	108-127
32415923-8	2020	We concluded that the combined therapy of calcitriol and sevelamer carbonate in chronic renal failure patients can significantly improve the therapeutic effect, and at the same time actively improve the serum parathyroid hormone level, which is a treatment model that can be popularized and applied.	sevelamer	57-76	parathyroid hormone	Homo sapiens	209-228